Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10098877 | STRONGBRIDGE | Methods and compositions for treating diabetes, metabolic syndrome and other conditions |
Jan, 2026
(2 years from now) | |
US10835530 | STRONGBRIDGE | Methods and compositions for treating diabetes, metabolic syndrome and other conditions |
Jan, 2026
(2 years from now) | |
US10517868 | STRONGBRIDGE | Methods and compositions for treating diabetes, metabolic syndrome and other conditions |
Jan, 2026
(2 years from now) | |
US9918984 | STRONGBRIDGE | Methods and compositions for treating diabetes, metabolic syndrome and other conditions |
Jan, 2026
(2 years from now) | |
US11478471 | STRONGBRIDGE | NA |
Jan, 2026
(2 years from now) | |
US11278547 | STRONGBRIDGE | Methods of treating disease with levoketoconazole |
Mar, 2040
(16 years from now) | |
US11020393 | STRONGBRIDGE | Methods of treating disease with levoketoconazole |
Mar, 2040
(16 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
Orphan Drug Exclusivity (ODE) | Dec 30, 2028 |
Drugs and Companies using LEVOKETOCONAZOLE ingredient
Market Authorisation Date: 30 December, 2021
Treatment: Treatment of endogenous hypercortisolemia in patients with cushing’s syndrome for whom surgery is not an option or has not been curative; During levoketoconazole dosage titration for the treatment of ...
Dosage: TABLET;ORAL
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic